PRECAUTIONS O
Information O
for O
Patients O
NOTE O
: O
In O
addition O
to O
information O
provided O
below O
, O
a O
Patient O
Medication O
Guide O
providing O
instructions O
for O
proper O
use O
of O
TOBI O
is O
contained O
inside O
the O
package O
. O

Safety O
Information O
TOBI O
is O
in O
a O
class O
of O
antibiotics O
that O
have O
caused O
hearing B-NonOSE_AE
loss I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
kidney B-NonOSE_AE
damage I-NonOSE_AE
, O
and O
harm B-NonOSE_AE
to I-NonOSE_AE
a I-NonOSE_AE
fetus I-NonOSE_AE
. O

Ringing B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
ears I-NonOSE_AE
and O
hoarseness B-NonOSE_AE
were O
two O
symptoms O
that O
were O
seen O
in O
more O
patients O
taking O
TOBI O
than O
placebo O
in O
research O
studies O
. O

Patients O
with O
cystic B-Not_AE_Candidate
fibrosis I-Not_AE_Candidate
can O
have O
many O
symptoms O
. O

Some O
of O
these O
symptoms O
may O
be O
related O
to O
your O
medications O
. O

If O
you O
have O
new O
or O
worsening O
symptoms O
, O
you O
should O
tell O
your O
doctor O
. O

Hearing B-NonOSE_AE
: O
You O
should O
tell O
your O
doctor O
if O
you O
have O
ringing B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
ears I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
or O
any O
changes B-NonOSE_AE
in I-NonOSE_AE
hearing I-NonOSE_AE
. O

Kidney B-NonOSE_AE
Damage I-NonOSE_AE
: O
Inform O
your O
doctor O
if O
you O
have O
any O
history O
of O
kidney B-Not_AE_Candidate
problems I-Not_AE_Candidate
. O

Pregnancy B-NonOSE_AE
: O
If O
you O
want O
to O
become O
pregnant B-NonOSE_AE
or O
are O
pregnant B-NonOSE_AE
while O
on O
TOBI O
, O
you O
should O
talk O
with O
your O
doctor O
about O
the O
possibility O
of O
TOBI O
causing O
any O
harm O
. O

Nursing O
Mothers O
: O
If O
you O
are O
nursing O
a O
baby O
, O
you O
should O
talk O
with O
your O
doctor O
before O
using O
TOBI O
. O

TOBI O
Packaging O
TOBI O
comes O
in O
a O
single O
dose O
, O
ready-to-use O
ampule O
containing O
300 O
mg O
tobramycin O
. O

Each O
foil O
pouch O
contains O
4 O
ampules O
, O
for O
2 O
days O
of O
TOBI O
therapy O
. O

Dosage O
The O
300 O
mg O
dose O
of O
TOBI O
is O
the O
same O
for O
patients O
regardless O
of O
age O
or O
weight O
. O

TOBI O
has O
not O
been O
studied O
in O
patients O
less O
than O
6 O
years O
old O
. O

Doses O
should O
be O
inhaled O
as O
close O
to O
12 O
hours O
apart O
as O
possible O
and O
not O
less O
than O
6 O
hours O
apart O
. O

You O
should O
not O
mix O
TOBI O
with O
dornase O
alfa O
( O
PULMOZYME O
( O
r O
) O
, O
Genentech O
) O
in O
the O
nebulizer O
. O

If O
you O
are O
taking O
several O
medications O
the O
recommended O
order O
is O
as O
follows O
: O
bronchodilator O
first O
, O
followed O
by O
chest O
physiotherapy O
, O
then O
other O
inhaled O
medications O
and O
, O
finally O
, O
TOBI O
. O

Treatment O
Schedule O
You O
should O
take O
TOBI O
in O
repeated O
cycles O
of O
28 O
days O
on O
drug O
followed O
by O
28 O
days O
off O
drug O
. O

You O
should O
take O
TOBI O
twice O
a O
day O
during O
the O
28-day O
period O
on O
drug O
. O

How O
To O
Administer O
TOBI O
THIS O
INFORMATION O
IS O
NOT O
INTENDED O
TO O
REPLACE O
CONSULTATION O
WITH O
YOUR O
PHYSICIAN O
AND O
CF O
CARE O
TEAM O
ABOUT O
PROPERLY O
TAKING O
MEDICATION O
OR O
USING O
INHALATION O
EQUIPMENT O
. O

TOBI O
is O
specifically O
formulated O
for O
inhalation O
using O
a O
PARI O
LC O
PLUSTM O
Reusable O
Nebulizer O
and O
a O
DeVilbiss O
( O
r O
) O
Pulmo-Aide O
( O
r O
) O
air O
compressor O
. O

TOBI O
can O
be O
taken O
at O
home O
, O
school O
, O
or O
at O
work O
. O

The O
following O
are O
instructions O
on O
how O
to O
use O
the O
DeVilbiss O
Pulmo-Aide O
air O
compressor O
and O
PARI O
LC O
PLUS O
Reusable O
Nebulizer O
to O
administer O
TOBI O
. O

You O
will O
need O
the O
following O
supplies O
: O
* O
TOBI O
plastic O
ampule O
( O
vial O
) O
* O
DeVilbiss O
Pulmo-Aide O
air O
compressor O
* O
PARI O
LC O
PLUS O
Reusable O
Nebulizer O
* O
Tubing O
to O
connect O
the O
nebulizer O
and O
compressor O
* O
Clean O
paper O
or O
cloth O
towels O
* O
Nose O
clips O
( O
optional O
) O
It O
is O
important O
that O
your O
nebulizer O
and O
compressor O
function O
properly O
before O
starting O
your O
TOBI O
therapy O
. O

Note O
: O
Please O
refer O
to O
the O
manufacturers O
' O
care O
and O
use O
instructions O
for O
important O
information O
. O

Preparing O
Your O
TOBI O
for O
Inhalation O
1 O
. O

Wash O
your O
hands O
thoroughly O
with O
soap O
and O
water O
. O

2a O
. O

TOBI O
is O
packaged O
with O
4 O
ampules O
per O
foil O
pouch O
. O

2b O
. O

Separate O
one O
ampule O
by O
gently O
pulling O
apart O
at O
the O
bottom O
tabs O
. O

Store O
all O
remaining O
ampules O
in O
the O
refrigerator O
as O
directed O
. O

3 O
. O

Lay O
out O
the O
contents O
of O
a O
PARI O
LC O
PLUS O
Reusable O
Nebulizer O
package O
on O
a O
clean O
, O
dry O
paper O
or O
cloth O
towel O
. O

You O
should O
have O
the O
following O
parts O
: O
* O
Nebulizer O
Top O
and O
Bottom O
( O
Nebulizer O
Cup O
) O
Assembly O
* O
Inspiratory O
Valve O
Cap O
* O
Mouthpiece O
with O
Valve O
* O
Tubing O
4 O
. O

Remove O
the O
Nebulizer O
Top O
from O
the O
Nebulizer O
Cup O
by O
twisting O
the O
Nebulizer O
Top O
counter-clockwise O
, O
and O
then O
lifting O
off O
. O

Place O
the O
Nebulizer O
Top O
on O
the O
clean O
paper O
or O
cloth O
towel O
. O

Stand O
the O
Nebulizer O
Cup O
upright O
on O
the O
towel O
. O

5 O
. O

Connect O
one O
end O
of O
the O
tubing O
to O
the O
compressor O
air O
outlet O
. O

The O
tubing O
should O
fit O
snugly O
. O

Plug O
in O
your O
compressor O
to O
an O
electrical O
outlet O
. O

6 O
. O

Open O
the O
TOBI O
ampule O
by O
holding O
the O
bottom O
tab O
with O
one O
hand O
and O
twisting O
off O
the O
top O
of O
the O
ampule O
with O
the O
other O
hand O
. O

Be O
careful O
not O
to O
squeeze O
the O
ampule O
until O
you O
are O
ready O
to O
empty O
its O
contents O
into O
the O
Nebulizer O
Cup O
. O

7 O
. O

Squeeze O
all O
the O
contents O
of O
the O
ampule O
into O
the O
Nebulizer O
Cup O
. O

8 O
. O

Replace O
the O
Nebulizer O
Top O
. O

Note O
: O
In O
order O
to O
insert O
the O
Nebulizer O
Top O
into O
the O
Nebulizer O
Cup O
, O
the O
semi-circle O
halfway O
down O
the O
stem O
of O
the O
Nebulizer O
Top O
should O
face O
the O
Nebulizer O
Outlet O
. O

9 O
. O

Attach O
the O
Mouthpiece O
to O
the O
Nebulizer O
Outlet O
. O

Then O
firmly O
push O
the O
Inspiratory O
Valve O
Cap O
in O
place O
on O
the O
Nebulizer O
Top O
. O

Note O
: O
The O
Inspiratory O
Valve O
Cap O
will O
fit O
snugly O
. O

10 O
. O

Connect O
the O
free O
end O
of O
the O
tubing O
from O
the O
compressor O
to O
the O
Air O
Intake O
on O
the O
bottom O
of O
the O
nebulizer O
, O
making O
sure O
to O
keep O
the O
nebulizer O
upright O
. O

Press O
the O
tubing O
on O
the O
Air O
Intake O
firmly O
. O

TOBI O
Treatment O
1 O
. O

Turn O
on O
the O
compressor O
. O

2 O
. O

Check O
for O
a O
steady O
mist O
from O
the O
Mouthpiece O
. O

If O
there O
is O
no O
mist O
, O
check O
all O
tubing O
connections O
and O
confirm O
that O
the O
compressor O
is O
working O
properly O
. O

3 O
. O

Sit O
or O
stand O
in O
an O
upright O
position O
that O
will O
allow O
you O
to O
breathe O
normally O
. O

4 O
. O

Place O
Mouthpiece O
between O
your O
teeth O
and O
on O
top O
of O
your O
tongue O
and O
breathe O
normally O
only O
through O
your O
mouth O
. O

Nose O
clips O
may O
help O
you O
breathe O
through O
your O
mouth O
and O
not O
through O
your O
nose O
. O

Do O
not O
block O
airflow O
with O
your O
tongue O
. O

5 O
. O

Continue O
treatment O
until O
all O
your O
TOBI O
is O
gone O
, O
and O
there O
is O
no O
longer O
any O
mist O
being O
produced O
. O

You O
may O
hear O
a O
sputtering O
sound O
when O
the O
Nebulizer O
Cup O
is O
empty O
. O

The O
entire O
TOBI O
treatment O
should O
take O
approximately O
15 O
minutes O
to O
complete O
. O

Note O
: O
If O
you O
are O
interrupted O
, O
need O
to O
cough O
or O
rest O
during O
your O
TOBI O
treatment O
, O
turn O
off O
the O
compressor O
to O
save O
your O
medication O
. O

Turn O
the O
compressor O
back O
on O
when O
you O
are O
ready O
to O
resume O
your O
therapy O
. O

6 O
. O

Follow O
the O
nebulizer O
cleaning O
and O
disinfecting O
instructions O
after O
completing O
therapy O
. O

Cleaning O
Your O
Nebulizer O
To O
reduce O
the O
risk O
of O
infection O
, O
illness O
or O
injury O
from O
contamination O
, O
you O
must O
thoroughly O
clean O
all O
parts O
of O
the O
nebulizer O
as O
instructed O
after O
each O
treatment O
. O

Never O
use O
a O
nebulizer O
with O
a O
clogged O
nozzle O
. O

If O
the O
nozzle O
is O
clogged O
, O
no O
aerosol O
mist O
is O
produced O
, O
which O
will O
alter O
the O
effectiveness O
of O
the O
treatment O
. O

Replace O
the O
nebulizer O
if O
clogging O
occurs O
. O

1 O
. O

Remove O
tubing O
from O
nebulizer O
and O
disassemble O
nebulizer O
parts O
. O

2 O
. O

Wash O
all O
parts O
( O
except O
tubing O
) O
with O
warm O
water O
and O
liquid O
dish O
soap O
. O

3 O
. O

Rinse O
thoroughly O
with O
warm O
water O
and O
shake O
out O
water O
. O

4 O
. O

Air O
dry O
or O
hand O
dry O
nebulizer O
parts O
on O
a O
clean O
, O
lint-free O
cloth O
. O

Reassemble O
nebulizer O
when O
dry O
, O
and O
store O
. O

5 O
. O

You O
can O
also O
wash O
all O
parts O
of O
the O
nebulizer O
in O
a O
dishwasher O
( O
except O
tubing O
) O
. O

Place O
the O
nebulizer O
parts O
in O
a O
dishwasher O
basket O
, O
then O
place O
on O
the O
top O
rack O
of O
the O
dishwasher O
. O

Remove O
and O
dry O
the O
parts O
when O
the O
cycle O
is O
complete O
. O

Disinfecting O
Your O
Nebulizer O
Your O
nebulizer O
is O
for O
your O
use O
only O
- O
Do O
not O
share O
your O
nebulizer O
with O
other O
people O
. O

You O
must O
regularly O
disinfect O
the O
nebulizer O
. O

Failure O
to O
do O
so O
could O
lead O
to O
serious O
or O
fatal B-NonOSE_AE
illness O
. O

Clean O
the O
nebulizer O
as O
described O
above O
. O

Every O
other O
treatment O
day O
, O
disinfect O
the O
nebulizer O
parts O
( O
except O
tubing O
) O
by O
boiling O
them O
in O
water O
for O
a O
full O
10 O
minutes O
. O

Dry O
parts O
on O
a O
clean O
, O
lint-free O
cloth O
. O

Care O
and O
Use O
of O
Your O
Pulmo-Aide O
Compressor O
Follow O
the O
manufacturer O
's O
instructions O
for O
care O
and O
use O
of O
your O
compressor O
. O

Filter O
Change O
: O
1 O
. O

DeVilbiss O
Compressor O
filters O
should O
be O
changed O
every O
six O
months O
or O
sooner O
if O
filter O
turns O
completely O
gray O
in O
color O
. O

Compressor O
Cleaning O
: O
1 O
. O

With O
power O
switch O
in O
the O
`` O
Off O
'' O
position O
, O
unplug O
power O
cord O
from O
wall O
outlet O
. O

2 O
. O

Wipe O
outside O
of O
the O
compressor O
cabinet O
with O
a O
clean O
, O
damp O
cloth O
every O
few O
days O
to O
keep O
dust O
free O
. O

Caution O
: O
Do O
not O
submerge O
in O
water O
; O
doing O
so O
will O
result O
in O
compressor O
damage O
. O

Storage O
Instructions O
You O
should O
store O
TOBI O
ampules O
in O
a O
refrigerator O
( O
2 O
degrees O
C-8 O
degrees O
C O
or O
36 O
degrees O
F O
-46 O
degrees O
F O
) O
. O

However O
, O
when O
you O
do O
n't O
have O
a O
refrigerator O
available O
( O
e.g. O
, O
transporting O
your O
TOBI O
) O
, O
you O
may O
store O
the O
foil O
pouches O
( O
opened O
or O
unopened O
) O
at O
room O
temperature O
( O
up O
to O
25 O
degrees O
C/77 O
degrees O
F O
) O
for O
up O
to O
28 O
days O
. O

Avoid O
exposing O
TOBI O
ampules O
to O
intense O
light O
. O

Unrefrigerated O
TOBI O
, O
which O
is O
normally O
slightly O
yellow O
, O
may O
darken O
with O
age O
; O
however O
, O
the O
color O
change O
does O
not O
indicate O
any O
change O
in O
the O
quality O
of O
the O
product O
. O

You O
should O
not O
use O
TOBI O
if O
it O
is O
cloudy O
, O
if O
there O
are O
particles O
in O
the O
solution O
, O
or O
if O
it O
has O
been O
stored O
at O
room O
temperature O
for O
more O
than O
28 O
days O
. O

You O
should O
not O
use O
TOBI O
beyond O
the O
expiration O
date O
stamped O
on O
the O
ampule O
. O

Additional O
Information O
Nebulizer O
: O
1-800-327-8632 O
Compressor O
: O
1-800-338-1988 O
TOBI O
: O
1-888-NOW-NOVA O
( O
1-888-669-6682 O
) O
Laboratory O
Tests O
Audiograms O
Clinical O
studies O
of O
TOBI O
did O
not O
identify O
hearing B-NonOSE_AE
loss I-NonOSE_AE
using O
audiometric O
tests O
which O
evaluated O
hearing O
up O
to O
8000 O
Hz O
. O

Physicians O
should O
consider O
an O
audiogram O
for O
patients O
who O
show O
any O
evidence O
of O
auditory B-NonOSE_AE
dysfunction I-NonOSE_AE
, O
or O
who O
are O
at O
increased O
risk O
for O
auditory B-NonOSE_AE
dysfunction I-NonOSE_AE
. O

Tinnitus B-NonOSE_AE
may O
be O
a O
sentinel O
symptom O
of O
ototoxicity B-NonOSE_AE
, O
and O
therefore O
the O
onset O
of O
this O
symptom O
warrants O
caution O
. O

Serum O
Concentrations O
In O
patients O
with O
normal O
renal O
function O
treated O
with O
TOBI O
, O
serum O
tobramycin O
concentrations O
are O
approximately O
1 O
mcg/mL O
1 O
hour O
after O
dose O
administration O
and O
do O
not O
require O
routine O
monitoring O
. O

Serum O
concentrations O
of O
tobramycin O
in O
patients O
with O
renal B-Not_AE_Candidate
dysfunction I-Not_AE_Candidate
or O
patients O
treated O
with O
concomitant O
parenteral O
tobramycin O
should O
be O
monitored O
at O
the O
discretion O
of O
the O
treating O
physician O
. O

The O
serum O
concentration O
of O
tobramycin O
should O
only O
be O
monitored O
through O
venipuncture O
and O
not O
finger O
prick O
blood O
sampling O
. O

Contamination O
of O
the O
skin O
of O
the O
fingers O
with O
tobramycin O
may O
lead O
to O
falsely O
increased O
measurements O
of O
serum O
levels O
of O
the O
drug O
. O

This O
contamination O
can O
not O
be O
completely O
avoided O
by O
hand O
washing O
before O
testing O
. O

Renal O
Function O
The O
clinical O
studies O
of O
TOBI O
did O
not O
reveal O
any O
imbalance O
in O
the O
percentage O
of O
patients O
in O
the O
TOBI O
and O
placebo O
groups O
who O
experienced O
at O
least O
a O
50 O
% O
rise B-NonOSE_AE
in I-NonOSE_AE
serum I-NonOSE_AE
creatinine I-NonOSE_AE
from O
baseline O
( O
see O
ADVERSE O
REACTIONS O
) O
. O

Laboratory O
tests O
of O
urine O
and O
renal O
function O
should O
be O
conducted O
at O
the O
discretion O
of O
the O
treating O
physician O
. O

Drug O
Interactions O
In O
clinical O
studies O
of O
TOBI O
, O
patients O
taking O
TOBI O
concomitantly O
with O
dornase O
alfa O
( O
PULMOZYME O
, O
Genentech O
) O
, O
beta-agonists O
, O
inhaled O
corticosteroids O
, O
other O
anti-pseudomonal O
antibiotics O
, O
or O
parenteral O
aminoglycosides O
demonstrated O
adverse O
experience O
profiles O
similar O
to O
the O
study O
population O
as O
a O
whole O
. O

Concurrent O
and/or O
sequential O
use O
of O
TOBI O
with O
other O
drugs O
with O
neurotoxic B-NonOSE_AE
, O
nephrotoxic B-NonOSE_AE
, O
or O
ototoxic B-NonOSE_AE
potential O
should O
be O
avoided O
. O

Some O
diuretics O
can O
enhance O
aminoglycoside O
toxicity O
by O
altering O
antibiotic O
concentrations O
in O
serum O
and O
tissue O
. O

TOBI O
should O
not O
be O
administered O
concomitantly O
with O
ethacrynic O
acid O
, O
furosemide O
, O
urea O
, O
or O
intravenous O
mannitol O
. O

The O
interaction O
between O
inhaled O
mannitol O
and O
TOBI O
has O
not O
been O
evaluated O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
A O
two-year O
rat O
inhalation O
toxicology O
study O
to O
assess O
carcinogenic B-NonOSE_AE
potential O
of O
TOBI O
has O
been O
completed O
. O

Rats O
were O
exposed O
to O
TOBI O
for O
up O
to O
1.5 O
hours O
per O
day O
for O
95 O
weeks O
. O

The O
clinical O
formulation O
of O
the O
drug O
was O
used O
for O
this O
carcinogenicity O
study O
. O

Serum O
levels O
of O
tobramycin O
of O
up O
to O
35 O
mcg/mL O
were O
measured O
in O
rats O
, O
in O
contrast O
to O
the O
average O
1 O
mcg/mL O
levels O
observed O
in O
cystic B-Not_AE_Candidate
fibrosis I-Not_AE_Candidate
patients O
in O
clinical O
trials O
. O

There O
was O
no O
drug-related O
increase O
in O
the O
incidence O
of O
any O
variety O
of O
tumor B-NonOSE_AE
. O

Additionally O
, O
TOBI O
has O
been O
evaluated O
for O
genotoxicity B-NonOSE_AE
in O
a O
battery O
of O
in O
vitro O
and O
in O
vivo O
tests O
. O

The O
Ames O
bacterial O
reversion O
test O
, O
conducted O
with O
5 O
tester O
strains O
, O
failed O
to O
show O
a O
significant O
increase B-NonOSE_AE
in I-NonOSE_AE
revertants I-NonOSE_AE
with O
or O
without O
metabolic O
activation O
in O
all O
strains O
. O

Tobramycin O
was O
negative O
in O
the O
mouse O
lymphoma B-NonOSE_AE
forward O
mutation O
assay O
, O
did O
not O
induce O
chromosomal B-NonOSE_AE
aberrations I-NonOSE_AE
in O
Chinese O
hamster O
ovary O
cells O
, O
and O
was O
negative O
in O
the O
mouse O
micronucleus O
test O
. O

Subcutaneous O
administration O
of O
up O
to O
100 O
mg/kg O
of O
tobramycin O
did O
not O
affect O
mating B-NonOSE_AE
behavior I-NonOSE_AE
or O
cause O
impairment B-NonOSE_AE
of I-NonOSE_AE
fertility I-NonOSE_AE
in O
male O
or O
female O
rats O
. O

Pregnancy O
Teratogenic O
Effects O
- O
Pregnancy O
Category O
D O
( O
See O
WARNINGS O
) O
No O
reproduction O
toxicology O
studies O
have O
been O
conducted O
with O
TOBI O
. O

However O
, O
subcutaneous O
administration O
of O
tobramycin O
at O
doses O
of O
100 O
or O
20 O
mg/kg/day O
during O
organogenesis O
was O
not O
teratogenic B-NonOSE_AE
in O
rats O
or O
rabbits O
, O
respectively O
. O

Doses O
of O
tobramycin O
> O
=40 O
mg/kg/day O
were O
severely O
maternally B-NonOSE_AE
toxic I-NonOSE_AE
to O
rabbits O
and O
precluded O
the O
evaluation O
of O
teratogenicity B-NonOSE_AE
. O

Aminoglycosides O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
( O
e.g. O
, O
congenital B-OSE_Labeled_AE
deafness I-OSE_Labeled_AE
) O
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

Ototoxicity B-NonOSE_AE
was O
not O
evaluated O
in O
offspring O
during O
nonclinical O
reproduction B-NonOSE_AE
toxicity I-NonOSE_AE
studies O
with O
tobramycin O
. O

If O
TOBI O
is O
used O
during O
pregnancy B-NonOSE_AE
, O
or O
if O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
taking O
TOBI O
, O
the O
patient O
should O
be O
apprised O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Nursing O
Mothers O
It O
is O
not O
known O
if O
TOBI O
will O
reach O
sufficient O
concentrations O
after O
administration O
by O
inhalation O
to O
be O
excreted O
in O
human O
breast O
milk O
. O

Because O
of O
the O
potential O
for O
ototoxicity B-NonOSE_AE
and O
nephrotoxicity B-NonOSE_AE
in O
infants O
, O
a O
decision O
should O
be O
made O
whether O
to O
terminate O
nursing O
or O
discontinue O
TOBI O
. O

Pediatric O
Use O
The O
safety O
and O
efficacy O
of O
TOBI O
have O
not O
been O
studied O
in O
pediatric O
patients O
under O
6 O
years O
of O
age O
. O

Geriatric O
Use O
Clinical O
studies O
of O
TOBI O
did O
not O
include O
patients O
aged O
65 O
years O
and O
over O
. O

Tobramycin O
is O
known O
to O
be O
substantially O
excreted O
by O
the O
kidney O
, O
and O
the O
risk O
of O
adverse O
reactions O
to O
this O
drug O
may O
be O
greater O
in O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

Because O
elderly O
patients O
are O
more O
likely O
to O
have O
decreased B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
it O
may O
be O
useful O
to O
monitor O
renal O
function O
( O
see O
WARNINGS O
- O
Nephrotoxicity O
; O
PRECAUTIONS O
- O
Serum O
Concentrations O
) O
. O

